Home > Boards > US Listed > Biotechs >

Lexicon Genetics (LXRX)

LXRX RSS Feed
Add LXRX Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 7/30/2021 2:09:53 PM - Followers: 54 - Board type: Free - Posts Today: 0

Results From SOLOIST and SCORED Outcomes Studies Presented at Late-Breaking Science Session of American Heart Association Scientific Sessions and Published in The New England Journal of Medicine

 
 
Lexicon Pharmaceuticals, Inc.
Mon, November 16, 2020, 10:02 PM EST
 
 

Sotagliflozin Significantly Reduced Total Cardiovascular Deaths, Heart Failure Hospitalization and Urgent Visits, Achieving Primary Endpoint in Both Studies

THE WOODLANDS, Texas, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that both the SOLOIST and SCORED Phase 3 studies achieved their primary endpoints by demonstrating statistically significant reductions in total cardiovascular deaths, hospitalizations for heart failure and urgent heart failure visits in patients treated with sotagliflozin as compared with placebo.

In the SOLOIST study, the primary endpoint was achieved with a hazard ratio (HR) of 0.67 (p<0.001) in people with type 2 diabetes and a recent hospitalization for worsening heart failure. In the SCORED study, the primary endpoint was achieved with a hazard ratio of 0.74 (p<0.001) in people with type 2 diabetes and chronic kidney disease with an estimated glomerular filtration rate (eGFR) of 25 to 60 ml/minute per 1.73 m² of body-surface area.

 

The key results from SOLOIST and SCORED were presented today at the Late-Breaking Science Session of the American Heart Association (AHA) Scientific Sessions 2020 and simultaneously published in The New England Journal of Medicine (NEJM) in two separate articles titled: “Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure” and “Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.” The articles may be accessed at www.nejm.org.

“Cardiovascular disease continues to be a leading cause of death in people with type 2 diabetes,” said Deepak L. Bhatt, M.D., M.P.H., executive director of Interventional Cardiovascular Programs at Brigham and Women's Hospital and a professor of medicine at Harvard Medical School and study chair and lead author for the NEJM publications of the SOLOIST and SCORED results. “SOLOIST demonstrates that early, in-hospital initiation of sotagliflozin in patients with worsening heart failure significantly reduces subsequent cardiovascular events, an effect that was consistent across groups with heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF). SCORED demonstrates that sotagliflozin significantly reduces heart failure events in a patient population with stage 3 and 4 chronic kidney disease and cardiovascular risk. Both studies add to the evidence that SGLT2 inhibition should be standard of care in heart failure, and the SCORED data reflecting a reduction in myocardial infarction and stroke and better glucose control in CKD patients suggest potential benefits from the dual SGLT1 and SGLT2 mechanism of this particular agent.”

 
 
LXRX
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
LXRX News: Statement of Changes in Beneficial Ownership (4) 08/03/2021 04:40:22 PM
LXRX News: Initial Statement of Beneficial Ownership (3) 08/03/2021 04:35:55 PM
LXRX News: Current Report Filing (8-k) 08/02/2021 07:24:17 AM
LXRX News: Current Report Filing (8-k) 08/02/2021 07:21:36 AM
LXRX News: Lexicon Posts Lower-than-Expected Quarterly Loss 08/02/2021 02:50:14 AM
News News Alert: Statement of Changes in Beneficial Ownership (4) 08/03/2021 04:40:22 PM
PostSubject
#687   Wouldn't be surprised to see this back over $6. BooDog 07/30/21 02:09:53 PM
#686   Been munching some of these dips. BooDog 07/28/21 10:46:26 AM
#685   Added 3.98 today. BooDog 07/06/21 03:54:02 PM
#684   Mine. I've been waiting forever for this BooDog 07/02/21 12:46:50 PM
#683   Many predict 15-20 relatively short term if they Guzzi62 01/15/21 05:47:57 AM
#682   * * $LXRX Video Chart 01-14-2021 * * ClayTrader 01/14/21 04:26:51 PM
#681   How high can this go? joro44 01/14/21 02:22:44 PM
#680   Yes a very good day, I am keeping Guzzi62 01/14/21 11:58:52 AM
#679   LXRX NEWS Lexicon Pharmaceuticals Provides Regulatory Update on BooDog 01/14/21 11:57:29 AM
#678   Liking the action here!! BooDog 01/08/21 03:39:13 PM
#677   Skimmed a few off @ 3.60. Looks BooDog 12/31/20 11:23:17 AM
#676   LXRX Golden cross alert BooDog 12/31/20 07:50:34 AM
#675   Gosh. What is this ipo_dude 12/21/20 10:02:20 AM
#674   ?? glad I'm not the only one simmons420 12/17/20 05:11:42 AM
#673   Took a few more under $3. Why BooDog 12/16/20 06:09:31 PM
#672   Here's the science with AC Bioscience. They BooDog 12/16/20 04:28:15 PM
#671   Lexicon Pharmaceuticals Enters Data Collaboration With AC Bioscience BooDog 12/16/20 04:15:19 PM
#670   Added 3.13. BooDog 12/16/20 04:13:04 PM
#669   So BCDA had an offering too and it ipo_dude 12/15/20 09:15:25 PM
#668   I should have added that if they get BooDog 12/11/20 12:19:11 PM
#667   Citigroup setting a price target of $6 was BooDog 12/11/20 11:36:14 AM
#666   Do not understand the 3.20 at all. Just joro44 12/11/20 10:06:53 AM
#665   $65M @ 3.20. Really? Figured that'd be BooDog 12/11/20 09:21:27 AM
#664   Lexicon Pharmaceuticals Receives Fast Track Designation From the BooDog 12/11/20 07:51:00 AM
#663   Glad i added on the dip!!! Bring on a deal! BooDog 12/10/20 06:26:48 PM
#662   Maybe a BUYER Company Daytrader0001 12/10/20 06:03:06 PM
#661   Thanks, looks like this will turn into a Guzzi62 12/08/20 09:21:48 PM
#660   * * $LXRX Video Chart 12-08-2020 * * ClayTrader 12/08/20 04:09:33 PM
#659   Awesome day here! powerbattles 12/08/20 01:45:46 PM
#658   Lexicon Pharmaceuticals shares are trading higher after Citigroup crudeoil24 12/08/20 12:08:42 PM
#657   This bad boy is strong... bleu22 12/08/20 11:54:38 AM
#656   Took a few more off @ 3.21. eom BooDog 12/08/20 10:55:28 AM
#655   when is next month Pt3 12/08/20 09:12:37 AM
#654   They are bullish on heart failure drug caused bleu22 12/08/20 08:44:58 AM
#653   FDA meeting next month, looks like they have bleu22 12/08/20 08:21:47 AM
#652   Be nice to know why they raised it. joro44 12/08/20 08:19:17 AM
#651   2020-12-08 12:59:00 GMT DJ Lexicon Pharma Price Target BooDog 12/08/20 08:05:14 AM
#650   Looking Good for LONG ALERT Play Daytrader0001 12/08/20 08:00:42 AM
#649   Nice going Guzzi! Added myself last Friday @ 1.60. BooDog 12/08/20 06:16:43 AM
#648   Gone up a lot over the last few Guzzi62 12/08/20 06:08:56 AM
#647   I do not own. JohnCM 12/04/20 04:00:37 PM
#646   Agree. If this reversal sticks we could BooDog 12/04/20 01:51:11 PM
#645   $2.00 would be big. JohnCM 12/04/20 01:42:25 PM
#644   A little more momentum and the walls will BooDog 12/04/20 01:34:27 PM
#643   Interesting ... JohnCM 12/03/20 09:36:56 AM
#642   Kinda looks like this could see another wave BooDog 12/02/20 02:34:22 PM
#641   What's next for LXRX after the positive SOLOIST novicetrader 11/26/20 03:50:14 PM
#640   * * $LXRX Video Chart 11-17-2020 * * ClayTrader 11/17/20 05:47:21 PM
#639   Same here, the news and the volume are bleu22 11/17/20 11:37:49 AM
#638   1.80's looks good for me to come out Imott 11/17/20 11:12:31 AM
PostSubject
Consent Preferences